

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. - 11. (Cancelled).
12. (Currently Amended) A method of reducing neuronal cell death in a mammal suffering from or susceptible to neurodegenerative disease, cerebral ischaemia, traumatic neuronal injury, paralysis, or spinal cord injury, comprising administering to the mammal an effective amount of a 3-substituted indolone ~~indolones~~ that is a C-Raf inhibitor or a pharmaceutically acceptable salt thereof sufficient to reduce neuronal cell death.
13. (Cancelled).
14. (Previously Presented) A method of reducing apoptotic neuronal cell death in a mammal, comprising administering to the mammal an effective amount of a C-Raf inhibitor, or a pharmaceutically acceptable salt thereof.
15. (Previously Presented) The method of claim 14, wherein said C-Raf inhibitor comprises {5- iodo-3-[(3,5-dibromo-4-hydroxyphenyl) methylene]-2-indolinone}.
16. (Cancelled).
17. (Currently Amended) The method of Claims 12 or 14 wherein said C-Raf inhibitor, ~~or a pharmaceutically acceptable salt, complex or prodrug thereof~~, comprises an oxindole derivative, or a pharmaceutically acceptable salt thereof.
18. (Currently Amended) The method of Claims 12 or 14 wherein said C-Raf inhibitor, ~~or a pharmaceutically acceptable salt, complex or prodrug thereof~~, comprises a benzamide derivative, or a pharmaceutically acceptable salt thereof.
19. (Previously Presented) The method of Claim 18 wherein said C-Raf inhibitor comprises N-[5-(3- dimethylaminobenzamide)-2-methylphenyl]-4-hydroxybenzamide.
20. (Currently Amended) The method of Claims 12 or 14 wherein said C-Raf inhibitor ~~or a pharmaceutically acceptable salt, complex or prodrug thereof~~, reduces neuronal cell death via B-

Raf regulation.

21. (Currently Amended) The method of Claim 20, wherein said C-Raf inhibitor ~~or a pharmaceutically acceptable salt thereof~~ reduces neuronal cell death by activating B-Raf.
22. (Previously Presented) The method of Claim 21, wherein said C-Raf inhibitor or a pharmaceutically acceptable salt thereof comprises an oxindole derivative.
23. (Previously Presented) The method of Claim 22, wherein said C-Raf inhibitor comprises {5- iodo-3-[(3,5-dibromo-4-hydroxyphenyl) methylene]-2-indolinone} or a pharmaceutically acceptable salt thereof.
24. (Previously Presented) The method of Claim 20, wherein said C-Raf inhibitor or a pharmaceutically acceptable salt, complex or prodrug thereof, comprises a benzamide derivative, or a pharmaceutically acceptable salt thereof.
25. (Previously Presented) The method of Claim 24, wherein said benzamide derivative comprises N-[5-(3- dimethylaminobenzamide)-2-methylphenyl]-4-hydroxybenzamide or a pharmaceutically acceptable salt thereof.
26. (Previously Presented) The method of Claim 21, wherein said C-Raf inhibitor or a pharmaceutically acceptable salt, complex or prodrug thereof, comprises a benzamide derivative, or a pharmaceutically acceptable salt thereof.
27. (Previously Presented) The method of Claim 26, wherein said benzamide derivative comprises N-[5-(3- dimethylaminobenzamide)-2-methylphenyl]-4-hydroxybenzamide or a pharmaceutically acceptable salt thereof.
28. (Previously Presented) A method of reducing neuronal cell death in a mammal, comprising administering an effective amount of a C-Raf inhibitor or a pharmaceutically acceptable salt thereof.
29. (Previously Presented) The method of Claim 28, wherein said C-Raf inhibitor comprises an oxindole derivative.
30. (Previously Presented) The method of Claim 28, wherein said C-Raf inhibitor comprises a benzamide derivative.

31. (Previously Presented) The method of Claims 28, wherein said C-Raf inhibitor reduces neuronal cell death via B-Raf regulation.
32. (Previously Presented) The method of Claim 31, wherein said C-Raf inhibitor reduces neuronal cell death by B-Raf activation.
33. (Previously Presented) The method of Claims 29 or 31 or 32, wherein said C-Raf inhibitor comprises {5- iodo-3-[(3,5-dibromo-4-hydroxyphenyl) methylene]-2-indolinone}.
34. (Previously Presented) The method of Claims 29 or 31 or 32, wherein said C-Raf inhibitor comprises N-[5-(3- dimethylaminobenzamide)-2-methylphenyl]-4-hydroxybenzamide.